Frontida BioPharm, a contract development and manufacturing organization located in Philadelphia, Pennsylvania and Aurora, Illinois, reports that the US Food and Drug Administration (FDA issued a closure letter for its Philadelphia manufacturing site on May 4, 2017. The closure letter was received eight months after the FDA issued a Warning Letter to Frontida based on an FDA inspection of the site occurring between June 15 and July 17, 2015, prior to Frontida’s purchase and operation of the facility.

Frontida also announces the launch of its operations expansion initiatives. Since acquiring the facilities on June 3, 2016, Frontida retained 155 positions at the existing sites and added more than 65 quality and scientific professionals. With the implementation of quality system improvements across the organization, Frontida plans to hire an additional 40 to 50 personnel in the next six months as it begins to launch new products in its Philadelphia and Aurora facilities.

Frontida BioPharm is a provider of drug-delivery technologies, product development, and manufacturing services for small and large pharmaceutical and consumer health companies.

Source: Frontida BioPharm